◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST MEDIUM

Saffron

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST MEDIUM

"Well-tolerated, low-risk botanical with the strongest replicated SSRI-comparable mood signal in the supplement literature. Three independent meta-analyses (Hausenblas 2013, Lopresti & Drummond 2014, Tóth 2019) show non-inferiority vs fluoxetine 20-40 mg/day and imipramine 100 mg/day in mild-to-moderate MDD at 28-30 mg/day standardized extract. Secondary signals for PMS (Agha-Hosseini 2008), SSRI-induced sexual dysfunction (Modabbernia 2012, Kashani 2013), MCI/AD (Akhondzadeh 2010 x2), pediatric ADHD (Baziar 2019), age-related macular degeneration (Falsini 2010), and sleep quality (Lopresti 2020). NOT a replacement for prescribed antidepressants in clinical MDD — saffron sits as a first-lever-to-try for subclinical low mood, an adjunct under clinician oversight for diagnosed depression, or a sexual-side-effect rescue for SSRI users. For this user (20yo MMA + business owner, no current mood/anxiety diagnosis, rhodiola + ashwagandha already covering the adaptogen layer), saffron is WATCH-LIST: low risk, modest signal, would consider if subjective baseline mood drifts and existing adaptogens are insufficient. Sourcing is easy (affron / Satiereal widely available); cost moderate ($15-30/month at affron 28 mg/day). Adulteration with safflower, marigold, or turmeric is rampant in the spice and bulk-supplement market — third-party-tested standardized extract is mandatory."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • 20-30, healthy male, no mood indication (this-archetype — Dylan)
    WATCH-LIST

    Modest signal in subclinical populations. Would consider if mood baseline drifts low; existing rhodiola + ashwagandha already cover the adaptogen layer. Saffron adds a serotonergic/GABAergic angle the others don't, but it's not an indicated addition for this user right now. Cost is moderate ($15-30/mo). Re-evaluate if subjective mood VAS or PHQ-9 drifts noticeably.

  • Athletic male 18-35, training and competition focus
    OPTIONAL-ADD

    Low risk, no ergogenic effect, no anabolic concern, not WADA-banned. Modest mood and sleep benefit available but rarely the highest-leverage addition to a training-focused stack. Higher-value compounds for this profile (creatine, ashwagandha for cortisol, vitamin D, omega-3) take precedence.

  • 30-50, executive maintenance / mild burnout
    OPTIONAL-ADD

    Reasonable low-risk addition for mood stability and stress-reactivity blunting; same mechanism rationale as for younger archetype.

  • 50+, MCI / cognitive decline
    STRONG-CANDIDATE

    Akhondzadeh AD trials show non-inferiority vs donepezil 10 mg/day with significantly better tolerability. Real cognitive indication. Pair with B-vitamins, omega-3, exercise — saffron is not a standalone fix but it's evidence-based at this age band.

  • Mild-to-moderate depression (not severe, no suicidality), prefers non-Rx route
    PRIMARY-PICK

    Best-evidenced botanical antidepressant. Non-inferiority vs fluoxetine 20 mg / imipramine 100 mg / citalopram 20 mg in the meta-analyses. 28-30 mg/day affron x 6-8 weeks for evaluation. Escalate to clinical psychiatric care if symptoms worsen or do not improve by week 8.

  • Diagnosed MDD on prescribed antidepressants
    ADJUNCT-UNDER-CLINICIA

    Lopresti 2019 add-on RCT shows tolerability acceptable under monitoring; theoretical serotonergic stacking risk exists. Not a substitute for prescribed therapy.

  • SSRI-induced sexual dysfunction (PSSD-adjacent or current-on-SSRI)
    STRONG-CANDIDATE

    adjunct. Modabbernia 2012 (men) and Kashani 2013 (women) both show significant improvement in sexual function domains at 30 mg/day. One of saffron's cleanest, most-replicated specific indications. Coordinate with prescribing clinician.

  • PMS / PMDD
    STRONG-CANDIDATE

    Agha-Hosseini 2008 cleanest gendered indication; 15 mg BID across cycles for 2-3 cycles.

  • ADHD-adjacent (especially if SSRI-history, methylphenidate-sensitive, or pediatric)
    POSSIBLE

    Baziar 2019 pediatric pilot vs methylphenidate is provocative but n=54, single-center, no adult replication, no head-to-head vs amphetamine. Consider as a low-risk trial *before* stimulant escalation — but the user-anecdote rationale ("I don't want to get diagnosed with ADHD so I'll take saffron") is far ahead of the evidence base.

  • Anxiety-prone, no MDD
    OPTIONAL-ADD

    Modest HAM-A signal. Ashwagandha or theanine are usually stronger anxiety-specific tools; saffron sits as a secondary lever.

  • Insomnia / poor sleep quality
    OPTIONAL-ADD

    Lopresti 2020 strongest sleep signal in the literature; not the strongest sleep-specific tool. Glycine, magnesium, sleep hygiene first.

  • Early age-related macular degeneration
    STRONG-CANDIDATE

    Falsini 2010 + Piccardi follow-up: 20 mg/day with sustained retinal flicker sensitivity improvement. Real ocular indication. Pair with AREDS2 formula.

  • Pregnant / breastfeeding
    AVOID

    High-dose saffron historically abortifacient; trial data in pregnancy absent; uterotonic mechanism at supratherapeutic doses. HARD-BLOCK.

  • Bipolar diagnosis
    CAUTION

    Antidepressant-mechanism agents theoretically risk inducing mania switch in bipolar disorder. No documented saffron-mania case reports, but the SSRI-like mechanism warrants caution.

▸ Subjective experience (deep)

At 28-30 mg/day standardized affron or Satiereal:

  • Onset is slow. Most users notice nothing in week 1. Subtle mood lift typically builds over weeks 2-4.
  • No acute felt effect. Unlike modafinil, caffeine, phenibut, or amphetamines, saffron has essentially no perceptible acute pharmacology at supplement doses. The change is retrospective — "I notice I'm not catastrophizing as much over the last two weeks."
  • "Floor under low mood" rather than a stimulant-like lift. No euphoria, no jitter, no motivational push. The reported subjective effect is described more as a reduction in the depth of bad days than an elevation of baseline.
  • Possible mild evening drowsiness if dosed PM. The GABA-A component is mild but real for some users — this is partly why the Lopresti 2020 sleep trial worked.
  • Stress reactivity reduction. Some users report less amplitude in stress responses (smaller spikes, faster recovery) — consistent with the HPA-axis modulation signal in rodent work.
  • Healthy-user effect is genuinely modest. Users without a baseline mood deficit usually report "I think it does something but I can't quite pin it." This matches the literature: effect sizes are largest in subclinical / mild-moderate populations and shrink toward null in healthy adults.
  • Honest variability. A subset of users (~10-15%) describe paradoxical mild anxiety or appetite-suppression in the first week; usually transient.

Effect is much subtler than SSRI dose-response but with vastly better tolerability. For users without a baseline mood issue, expect modest-to-no felt effect — this is not a "feel it on day one" supplement.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal. Trial data extends through 22 weeks (Akhondzadeh AD donepezil-comparator) with sustained effect; the 11-trial Tóth meta does not show effect-size decay with longer trial durations.
  • Recommended cycle: Daily continuous through 12 weeks for mood-stability use; optional 2-week break to reassess baseline. For AD / MCI use, indefinite continuation per the trial protocols.
  • Reset protocol: Not typically needed.
  • Long-term safety beyond 22 weeks: Limited published data. Given GRAS status as a food spice and the very modest pharmacology at 30 mg, presumed safe with annual reassessment.
  • Mechanism-of-tolerance question: Saffron's primary effect is not depleting a neurotransmitter pool, so the receptor-downregulation tolerance pattern seen with SSRIs or stimulants is mechanistically unlikely. Anecdotal "wore off" reports probably reflect (a) regression of an expectancy/novelty effect, (b) underlying mood issue progressing past saffron's effect ceiling, or (c) consistency drift in the actual dosing.
▸ Stacking deep dive

Synergistic with

  • rhodiola: Different mechanism (rhodiola = MAO + monoamine reuptake nudge + adaptogenic HPA modulation; saffron = SSRI-like + GABAergic + antioxidant). Logical AM/PM split. Both modest mood signals from non-overlapping pathways. Already in this user's V4 stack — saffron would layer cleanly.
  • ashwagandha: Complementary — ashwagandha = cortisol attenuation via HPA-axis modulation; saffron = direct mood/serotonergic. Strong pairing for combined stress-plus-mood indication. Also already V4-locked for this user.
  • l-theanine: Both modulate GABAergic tone with non-overlapping mechanisms (theanine = AMPA antagonism + glutamate transporter modulation; safranal = GABA-A allosteric). Common stack for anxiety-mood. Already V4 for this user.
  • magnesium-l-threonate: Cognitive and sleep complementarity via NMDA modulation. Already in V4.
  • 5-HTP (low dose): Theoretical complement — 5-HTP raises serotonin substrate availability, saffron may slow reuptake/breakdown. Caution: stack with vigilance for serotonin syndrome signs; do not combine at higher doses.

Caution / avoid stacking

  • SSRIs at full clinical dose: Theoretical additive serotonergic effect. Most trials run saffron as monotherapy or as SSRI alternative. Use only with clinician oversight. The Lopresti 2019 add-on trial (saffron + SSRI vs SSRI alone) actually showed no serotonin syndrome events, but trial monitoring was tight and individual variability is unknown.
  • MAOIs (phenelzine, tranylcypromine): Saffron has weak in-vitro MAO-A/B inhibition. Combining with prescription non-selective MAOIs carries theoretical hypertensive crisis / serotonin syndrome risk. Avoid.
  • Selegiline at MAO-B-selective doses (1-2.5 mg/day): Likely OK; no reports of issue. At >10 mg/day selegiline loses MAO-B selectivity — increases concern.
  • St. John's Wort: Both serotonergic; additive risk. Avoid co-administration.
  • Tramadol, fentanyl, meperidine: All have serotonergic components — theoretical interaction at higher saffron doses.
  • Warfarin / high-dose antiplatelets: Mild antiplatelet effect; caution at supratherapeutic saffron doses or therapeutic anticoagulation.

Neutral / safe co-administration

Most V4/V5 stack compounds: NAC, citicoline, magnesium, phosphatidylserine, vitamin D3+K2, creatine, vitamin C, alpha-GPC, modafinil (different mechanism), bromantane, taurine, beta-alanine, peptides (BPC-157, TB-500, Semax, Selank, Adamax). No documented interactions.

▸ Drug interactions deep dive
  • SSRIs / SNRIs / TCAs: Theoretical additive serotonergic effect; monitor for serotonin syndrome at full clinical SSRI doses. Lopresti 2019 add-on RCT shows tolerability is acceptable under monitoring, but this is not blanket clearance.
  • MAOIs (non-selective): Theoretical interaction via crocetin's in-vitro MAO-A inhibition. Avoid.
  • Tramadol, meperidine, fentanyl, dextromethorphan: Serotonergic interaction theoretical; caution at higher saffron doses.
  • Warfarin / DOACs / antiplatelets: Mild antiplatelet effect at high saffron doses; caution.
  • Antihypertensives: Saffron may have modest BP-lowering effect at chronic dosing; monitor in hypotensive patients or those on aggressive antihypertensive regimens.
  • CYP3A4 / CYP2D6 substrates: Minimal documented interaction at standard 30 mg/day doses. Crocetin is metabolized primarily via glucuronidation and oxidation rather than CYP-driven Phase I.
  • Hormonal contraceptives: No documented interaction.
  • Modafinil / armodafinil: No documented interaction. The user's planned modafinil protocol would stack cleanly with saffron mechanistically (different systems).
  • Alcohol: No clinically meaningful interaction at supplement doses. (User: zero alcohol baseline; non-issue.)
▸ Pharmacogenomics

Saffron pharmacogenomics is not well characterized — no established polymorphism associations with saffron clinical response have been published. A few mechanistic predictions can be made from saffron's mechanism profile, but treat them as inferential rather than data-validated:

  • SLC6A4 (serotonin transporter, 5-HTTLPR): S/S short-allele carriers have less SSRI response and possibly more SSRI side effects. By extension, S/S carriers might respond differently to saffron's mild SRI activity — possibly less robust response, possibly fewer side effects. No human data validates this.
  • MTHFR C677T / A1298C: Hyperhomocysteinemia and reduced methylation capacity associate with depression risk. Saffron does not affect methylation pathways directly, so MTHFR status should not modulate response. (Genuinely unknown though.)
  • COMT Val158Met: Met/Met (slower dopamine clearance) carriers may have higher baseline anxiety; theoretically GABAergic agents (safranal component) might benefit them more. Speculative.
  • CYP3A4 / CYP2D6 / CYP2C19: Modest relevance since crocetin doesn't lean on Phase I oxidation. Not a meaningful tuning variable.

For this user: 23andMe results land June 2026. SLC6A4 raw-data pull via Promethease will flag short-allele status, but actionability is limited — there's no validated saffron-dose-by-genotype protocol. Use trial-of-one response (PHQ-9 + VAS at week 4-6) rather than genotype-driven dosing.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
affron® (Pharmactive) standardized 3.5% Lepticrosalides Life Extension, Doctor's Best, Designs for Health, Pure Encapsulations $15-25 / 30-60 caps 28 mg High Trial-replicating standardization. 11+ human RCTs use this exact extract. Default pick.
Satiereal® (INOREAL) standardized Pure Encapsulations, Thorne $20-30 / 30-60 caps 30 mg High Trial-replicating alternative to affron. Used in some early Iranian and European RCTs. Functionally interchangeable for clinical purposes.
Generic saffron extract (unstandardized) Various $5-15 Low-medium Variable potency; trial findings may not transfer. Adulteration risk high. Avoid unless third-party testing certificate available.
Whole saffron threads (kitchen / spice grade) Specialty spice shops, Persian / Spanish import $5-15 / gram N/A NOT supplement-grade. Therapeutic dose would require ~150-200 mg threads/day — hard to consume daily, impossible to dose-control. Even high-end spice grade is frequently adulterated (see below).

Saffron adulteration — a serious sourcing problem. Saffron is among the world's most-adulterated agricultural products. Common adulterants in the spice market and unregulated supplement market include safflower, calendula (marigold), turmeric, beet root, and dyed corn silk. ISO/TS 3632-2 UV-Vis spec testing cannot detect adulterants below ~20% w/w; HPLC/PDA/ESI-MS can detect adulterants down to 2-5% w/w (Sabatino 2011, PMID 22312727). DART-TQ and UHPLC-HRMS methods extend detection below 1%. Practical implication: unstandardized "saffron extract" supplements from low-trust vendors may be substantially adulterated and trial findings absolutely do not transfer. The affron / Satiereal standardization is real protection — Pharmactive publishes HPLC fingerprinting on Lepticrosalides composition.

For this user: If trialing, affron 28 mg/day from Life Extension or Doctor's Best (~$18-22/mo on Amazon or iHerb) is the cleanest path. Skip any unstandardized "saffron extract" SKU regardless of price. Costco / generic spice-aisle saffron is irrelevant for supplement use.

▸ Biomarkers to track (deep)
  • Baseline (before starting):
    • PHQ-9 (mood, validated 9-item depression screen)
    • GAD-7 or HAM-A (anxiety)
    • PSQI or simple sleep VAS (sleep quality)
    • PSS (perceived stress, 10-item)
    • DASS-21 (Depression, Anxiety, Stress Scale — used in many affron trials, including Lopresti 2025)
    • Subjective mood 1-10 daily VAS for 7-14 days pre-dose to establish baseline variance
    • For users with sexual function indication: IIEF (men) or FSFI (women)
    • For AD / MCI indication: MoCA or ADAS-cog if access
  • During use:
    • Weekly subjective mood VAS for 6-8 weeks
    • Same primary scale (PHQ-9, GAD-7, etc.) at week 4, week 8, week 12
    • Side-effect log (especially first 2 weeks for GI / appetite, week 1 for paradoxical anxiety)
  • Post-cycle (if cycling or stopping):
    • Re-baseline scales 2 weeks after stopping
    • Note any rebound or return-to-baseline pattern — this distinguishes pharmacological effect from expectancy / regression-to-mean
▸ Controversies / open debates Live debate
  • Mechanism remains under-characterized. The consistent clinical signal across 25+ RCTs predates a full mechanistic story. The "serotonergic modulation" framing is dominant but rests on animal and in-vitro data that may not fully explain the human effect at 30 mg/day. Crocetin's in-vitro MAO-A inhibition is at concentrations that may not be physiologically attained from oral 30 mg dosing.
  • SSRI non-inferiority claim is real but qualified. Most head-to-head trials are in mild-to-moderate MDD with relatively small samples (n=40-80), run primarily by Iranian research groups (Akhondzadeh, Noorbala, Modabbernia, Mazidi). Western replication is thinner; effect sizes may be inflated by methodology, geographic publication bias, or the placebo-response asymmetry common in mild-MDD trials. The Tóth 2019 meta is the most-rigorous synthesis and supports the claim — but the underlying RCT corpus is geographically narrow.
  • Standardization is essential and frequently absent. Generic saffron extract without affron / Satiereal grade is highly variable; trial findings may not transfer. Adulteration with safflower, calendula, turmeric, beet root, and dyed corn silk is rampant in both the spice and unregulated supplement markets. The HPLC/PDA literature (Sabatino 2011) documents this clearly. Cheap saffron is often not saffron.
  • Long-term safety beyond 22 weeks has limited published data, though the GRAS-spice base provides reasonable confidence at supplement doses.
  • Dosing has converged on 28-30 mg/day across virtually all trials; very few RCTs test higher doses, so the dose-response curve above 30 mg is poorly characterized. Higher doses are not validated as more effective and do raise toxicity concerns.
  • Affron vs Satiereal interchangeability: Both are well-trialed and use HPLC-defined standardization, but minimal head-to-head data exists. They are commercially marketed as equivalent for mood; trial-replicating fidelity favors using whichever extract the relevant trial used (affron for mood/sleep/youth/affron-named trials; Satiereal for older Iranian protocol).
  • The "Iranian research group dominance" question: The 2005-2015 era of saffron-depression research was heavily Iranian (especially Akhondzadeh / Tehran). This isn't inherently problematic — Iranian research on Persian medicinal plants has methodological credibility — but Western replication is still thin and the field would benefit from larger, multi-center Western trials. Lopresti's Australia-based affron program is the closest existing replication.
  • ADHD signal is provocative but premature. The Baziar 2019 vs-methylphenidate result is striking and has generated heavy supplement-market promotion, but it's a single 54-patient pediatric pilot. No adult data. No head-to-head vs amphetamine. No replication. Treating saffron as ADHD-equivalent to MPH on the basis of this trial alone is overreach. (Including the user-anecdote in the Discord excerpt above — well-intentioned but evidentially thin.)
  • Anhedonia-specific signal: A 2025 trial (Tartt et al., MDPI Molecules — PMC11891950) suggests affron has antianhedonic effect distinct from generic antidepressant signal in both rat and human cohorts. If replicated, this would carve out a specific niche for saffron in anhedonic-subtype depression.
▸ Verdict change log
  • 2026-05-14 — Verdict: WATCH-LIST. Confidence: MEDIUM. Graduated to thorough research-pass. Verdict unchanged from 2026-05-10 — the deeper review reinforces the original assessment. Well-tolerated, low-risk, modest mood + sleep signal with the strongest replicated SSRI-comparable signal in the supplement literature. Not a substitute for prescribed antidepressants. For this user (20yo, no current mood indication), would consider if mood baseline drifts low; existing rhodiola + ashwagandha cover most of the targeted use case. Key additions this pass: PMID corrections (several existing citations were misattributed — Hausenblas/Lopresti/Dwyer cross-mapping now correct), Tóth 2019 promoted to lead meta-analysis, Kell 2017 (PMID 28735826) correctly attributed as the pivotal affron-in-subthreshold trial (was previously misnamed "Lopresti 2017"), Baziar 2019 ADHD trial newly cited at correct PMID, Falsini 2010 AMD trial added with correct PMID, adulteration sourcing section expanded.
  • 2026-05-10 — Initial verdict: WATCH-LIST. Medium research-pass.
▸ Open questions / gaps Open
  1. Western replication of the Iranian RCT corpus — would strengthen confidence in the SSRI non-inferiority claim. Lopresti's Australian affron program is the closest existing replication but uses primarily subclinical populations.
  2. Long-term (>22 weeks) safety and efficacy data — Akhondzadeh AD trial is the longest published, and even that is short for chronic mood-stability use.
  3. Optimal dosing above 30 mg/day — dose-response curve poorly characterized; higher-dose efficacy not established and toxicity concerns rise.
  4. Mechanistic clarification — which active (crocins, crocetin, safranal) drive the mood effect, and via which receptor system, remains unresolved.
  5. Affron vs Satiereal head-to-head data — both well-trialed individually, no direct comparison published.
  6. Real-world interaction with full-dose SSRI therapy — Lopresti 2019 add-on trial is a starting point; broader monitoring data lacking.
  7. Adult ADHD efficacy — Baziar 2019 is pediatric only; adult head-to-head vs stimulants or atomoxetine has not been published.
  8. Anhedonia-specific signal (Tartt 2025) — needs replication. If real, would be a distinct niche.
  9. PSSD (post-SSRI sexual dysfunction) — Modabbernia and Kashani used current-on-SSRI populations; no data on post-discontinuation PSSD specifically.
  10. Bipolar mania-switch risk — no documented cases, but no formal exclusion data either. Theoretical caution standing.

References

Tóth et al. 2019 — Saffron meta-analysis (Planta Med)

pubmed.ncbi.nlm.nih.gov · 2019
View Study

Lopresti & Drummond 2014 — Saffron systematic review (Hum Psychopharmacol)

pubmed.ncbi.nlm.nih.gov · 2014
View Study

Hausenblas et al. 2013 — Saffron MDD meta-analysis (J Integr Med)

pubmed.ncbi.nlm.nih.gov · 2013
View Study

Noorbala et al. 2005 — Saffron vs fluoxetine head-to-head (J Ethnopharmacol)

pubmed.ncbi.nlm.nih.gov · 2005
View Study

Akhondzadeh et al. 2010 — Saffron vs donepezil in mild-moderate AD (Psychopharmacology)

pubmed.ncbi.nlm.nih.gov · 2010
View Study

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…